Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.53 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11533737 | 0.98 | MEN1 (0.58) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| Hydrochloric Acid SCHEMBL2673496 | 0.98 | MEN1 (0.58) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL4427076 | 0.89 | GAA (0.54) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL3810502 | 0.89 | GAA (0.54) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL3810424 | 0.89 | GAA (0.54) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| Acetic Acid SCHEMBL3958555 | 0.89 | SIGMAR1 (0.54) | ALDH1A1MEN1KMT2ASIGMAR1TEAD1 | |
| Hydrochloric Acid SCHEMBL4425500 | 0.87 | GAA (0.52) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| Hydrochloric Acid SCHEMBL4427412 | 0.87 | GAA (0.52) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| Hydrochloric Acid SCHEMBL4432892 | 0.87 | GAA (0.52) | ALDH1A1MEN1KMT2AKDM4ESIGMAR1 | |
| Trifluoroacetic Acid SCHEMBL1920595 | 0.85 | ARG1 (0.52) | ALDH1A1MEN1KMT2ASIGMAR1TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732896-B1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMA INC (US) | 2012-12-12 | — | — | EP | claimed |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-12528796-B2 | Modulators of RAS GTPase | TOSK, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220227740-A1 | Modulators of RAS GTPase | TOSK, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| US-5438064-A | For suppressing the binding of bradykinins to pain receptors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-01 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| EP-0111397-B1 | ISOINDOLE DERIVATIVES, PREPARATION, AND USES | Bristol-Myers Company (US) | 1989-03-01 | — | — | EP | disclosed |
| US-4600758-A | 5-SULFAMOYL-3-OXOISOINDOLES WITH ARLYPIPERIDINYL MOIETIES, DIURETICS, HYPOTENSIVES | MEAD JOHNSON & COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-4495194-A | HYPOTENSIVE AGENTS; DIURETICS | MEAD JOHNSON & COMPANY (US) | 1985-01-22 | — | — | US | disclosed |
| EP-0111397-A1 | Isoindole derivatives, preparation, and uses | Bristol-Myers Company (US) | 1984-06-20 | — | — | EP | disclosed |
| US-4289781-A | Anti-psychotic phthalimidine derivatives | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1981-09-15 | — | — | US | disclosed |
| EP-0026749-A1 | Phthalimidine derivatives and pharmaceutical compositions containing them | Astra Läkemedel Aktiebolag (SE) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | SLC18A2, SLC6A3, SLC6A4 | ALDH1A1 776/4885MEN1 4335/4885KMT2A 1679/4885 |
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | ALDH1A1 1133/4885MEN1 895/4885KMT2A 2563/4885 |
| US-20220227740-A1 | Modulators of RAS GTPase | KRAS, HRAS, NRAS | ALDH1A1 4302/4885MEN1 503/4885KMT2A 3199/4885 |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885MEN1 924/4885KMT2A 2316/4885 |
| US-11963954-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885MEN1 924/4885KMT2A 2316/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | ALDH1A1 1378/4885MEN1 1049/4885KMT2A 1920/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | ALDH1A1 1996/4885MEN1 924/4885KMT2A 2316/4885 |
| US-12528796-B2 | Modulators of RAS GTPase | KRAS, NRAS, HRAS | ALDH1A1 4254/4885MEN1 2621/4885KMT2A 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.